Testing JMT101 with chemo for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of a targeted therapy (JMT101) with chemotherapy for a type of lung cancer called squamous cell non-small cell lung cancer that has a specific marker (EGFR). It is for patients whose cancer has gotten worse after prior immunotherapy and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have squamous cell non-small cell lung cancer with high EGFR levels and no other known gene changes.
- Your cancer has progressed after you received both immunotherapy (like Keytruda or Opdivo) and platinum chemotherapy.
- You have at least one tumor that can be measured on scans.
- You are able to get out of bed and care for yourself (ECOG score 0 or 1).
- Your liver, kidney, and bone marrow function are adequate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted drug (JMT101) combined with another targeted therapy (osimertinib) versus standard chemotherapy for people with a specific type of advanced lung cancer. It is for those whose tumors have an EGFR exon 20 insertion mutation and who have not received prior treatment for advanced disease.
This trial tests a new drug called TMT101 for people with advanced pancreatic cancer or non-small cell lung cancer who have already tried other treatments. The goal is to see if TMT101 is safe and works against the cancer.
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
This trial is testing a new medicine called JMT106 for people with advanced solid tumors (cancers that have spread or can't be removed). It's for patients whose cancer has not responded to or can't use other treatments, and who have not had a therapy targeting a specific protein (GPC3) before.
This trial tests a new combination of two drugs — JMT101 (an antibody that targets EGFR) and mitoxantrone liposome (a chemotherapy in a special fatty bubble) — for people with nasopharyngeal cancer that has stopped responding to other treatments like PD-1/PD-L1 inhibitors and platinum-based chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer.
This trial tests a new drug called TJ101 for people with advanced solid tumors who have tried standard treatments or have no standard options. It aims to see if the drug is safe and how well it works.
Hear when a new Squamous Cell Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.